India, June 29 -- XtalPi (2228.HK) announced an expanded research collaboration with Pfizer (PFE) to develop a next-generation molecular modeling platform for drug discovery. The initiative aims to enhance the accuracy of advanced physics-based methods by integrating them with the speed, scalability, and broad coverage of cutting-edge AI models, optimizing the discovery and development of small-molecule medicines.
The companies will focus on developing more accurate predictive models to Pfizer's proprietary chemical space, with the aim of further empowering small molecule drug discovery and development across a broader range of research applications. In the collaboration, XtalPi will deploy its XFEP platform, from parameter customization t...